A carregar...
Orphan Drugs In Development For The Treatment Of Friedreich’s Ataxia: Focus On Omaveloxolone
Friedreich’s Ataxia (FRDA) is a devastating and progressive ataxia, marked by mitochondrial dysfunction and oxidative stress. Nrf2 activators such as omaveloxolone (Omav) modulate antioxidative mechanisms, and thus may be viable therapeutic agents in FRDA.
Na minha lista:
| Publicado no: | Degener Neurol Neuromuscul Dis |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6800542/ https://ncbi.nlm.nih.gov/pubmed/31686946 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DNND.S180027 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|